nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
The science of collecting and analyzing biologic or health data using statistical methods. Biostatistics may be used to help learn the possible causes of a disease in a certain group of people. Also called biometry and biometrics. (NCI) Blind
The "Learn" section of HPA includes educational resources, including information regarding antibody-based applications and techniques, a histology dictionary and educational 3D videos. The dictionary is an interactive tool for free full-screen exploration of whole slide images of normal human organs and tissues, cancer tissues and cell structures, guided with detailed annotations of all major structural elements. Educational videos have been produced by HPA, depicting the exploration of the human body in 3D, using antibody-based profiling of tissues and light sheet microscopy. The movies are available at the HPA website as well as on a YouTube channel. Datasets used in HPA are made freely available to encourage further studies within the research community. Access to the extensive datasets is given through the downloadable data page of HPA, wherein 29 different downloadable files are available, containing genome‐wide data across various assays.
=== Other === Labial fusion, also called labial adhesion, is the fusion of the labia minora. This affects a number of young girls and is not considered unduly problematic. The condition can usually be treated using creams, or it may right itself with the release of hormones at the onset of puberty. Clitoromegaly is an enlarged clitoris caused by either anabolic steroids or an intersex condition. Vulvodynia is chronic pain in the vulvar region. There is no single identifiable cause. A subtype of this is vulvar vestibulitis but since this is not thought to be an inflammatory condition it is more usually referred to as vestibulodynia. Vulvar vestibulitis usually affects pre-menopausal women. Pudendal nerve entrapment can cause sharp pain or numbness in the vulva. This condition can be caused by activities such as cycling, giving birth, or prolonged sitting. A number of skin disorders such as lichen sclerosus, and lichen simplex chronicus can affect the vulva. Crohn's disease of the vulva is an uncommon form of metastatic Crohn's disease, which manifests as a skin condition showing as hypertrophic lesions or vulvar abscesses. Papillary hidradenomas are nodules that can ulcerate and are mostly found on the skin of the labia or of the interlabial folds. Another more complex ulcerative condition is hidradenitis suppurativa, which is characterised by painful cysts that can ulcerate, and recur, and can become chronic lasting for many years. Chronic cases can develop into squamous cell carcinomas.
Sources: en.wikipedia.org
== Diagnosis == The diagnosis of IRIS is clinical. There is no universal definition of IRIS, however there is general consensus that most of the following criteria should be met to make the diagnosis:
An international consortium of researchers from 10 countries began sequencing the tomato genome in 2004. A prerelease version of the genome was made available in December 2009. The complete genome for the cultivar Heinz 1706 was published on 31 May 2012 in Nature. The latest reference genome published in 2021 had 799 MB and encodes 34,384 (predicted) proteins, spread over 12 chromosomes. The first commercially available genetically modified food was a tomato called Flavr Savr, which was engineered to have a longer shelf life. It could be vine ripened without compromising shelf life, which was expected to improve the flavor over ethylene-ripened tomatoes. However, it was not firmer than its unmodified parent, to the disappointment of its creators, who originally wanted to create a vine-ripened tomato that could survive machine-picking. The parent variety was also subpar in terms of yields. As a result, the product was not commercially successful, and was sold only until 1997. When the Mesoamericans domesticated tomatoes, they selected for less bitter fruits. This corresponded to the increased activity of a 2-oxoglutarate-dependent dioxygenase called 23DOX (synonym GAME31) during fruit ripening, which converts the bitter and slightly toxic α-tomatine into hydroxytomatine, which is eventually converted into the non-bitter and non-toxic esculeoside A.
Cardiac markers are biomarkers measured to evaluate heart function. They can be useful in the early prediction or diagnosis of disease. Although they are often discussed in the context of myocardial infarction, other conditions can lead to an elevation in cardiac marker level. Cardiac markers are used for the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome and for management and prognosis in patients with diseases like acute heart failure. Most of the early markers identified were enzymes, and as a result, the term "cardiac enzymes" is sometimes used. However, not all of the markers currently used are enzymes. For example, in formal usage, troponin would not be listed as a cardiac enzyme.
Sources: en.wikipedia.org
=== Available forms === OHPH was provided as a 125 mg/1 mL oil solution for use by intramuscular injection. In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations. It was used in Tocogestan, a combination of 50 mg progesterone, 200 mg OHPH, and 250 mg α-tocopherol palmitate (vitamin E) in oil solution for use by intramuscular injection. It was also used in Triormon Depositum (estradiol dibutyrate, testosterone caproate, and OHPH) and Trioestrine Retard (estradiol diundecylate, testosterone cyclohexylpropionate, and OHPH). OHPH was a component of the experimental preparation Trophobolene (or Trophoboline), which also contained estrapronicate (estradiol nicotinate propionate) and nandrolone undecanoate, as well.
== Beryllium-7 == Beryllium-7 is an isotope with a half-life of 53.22 days that is generated naturally as a cosmogenic nuclide. It is also a nuisance byproduct in nuclear reactors and accelerators. The rate at which the short-lived 7Be is transferred from the air to the ground is controlled in part by the weather. 7Be decay in the Sun (the half-life in stars can be greatly different from the normal as it is a free rather than a bound electron that is captured) is one of the sources of solar neutrinos, and the first type ever detected using the Homestake experiment. Presence of 7Be in sediments is often used to establish that they are fresh, i.e. less than about 3–4 months in age, or about two half-lives of 7Be.
Trelagliptin (trade name Trelaglip, Zafatek) is a pharmaceutical drug used for the treatment of type 2 diabetes (diabetes mellitus).Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan and India for the treatment of type 2 diabetes mellitus. Zuventus Healthcare introduced Trelagliptin in India (2025) under the brand name Trelaglip®.
This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH−NH2 group of donors with oxygen as acceptor. The systematic name of this enzyme class is L-amino-acid:oxygen oxidoreductase (deaminating). This enzyme is also called ophio-amino-acid oxidase. As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1F8R, PDB: 1F8S, PDB: 1REO, PDB: 1TDK, PDB: 1TDN, PDB: 1TDO, PDB: 2IID, PDB: 2JAE, PDB: 2JB1, PDB: 2JB2, and PDB: 2JB3.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.